Phase III Randomised Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

Trial Profile

Phase III Randomised Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Lymphoproliferative disorders
  • Focus Therapeutic Use
  • Acronyms IDRIS
  • Most Recent Events

    • 28 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 07 Nov 2016 Planned End Date changed from 30 Jun 2020 to 1 Dec 2025.
    • 07 Nov 2016 Planned primary completion date changed from 1 Dec 2022 to 1 Oct 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top